Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.
about
Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced diseaseSecond or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced diseaseMoving beyond Karnofsky and ECOG Performance Status Assessments with New TechnologiesSurgical management of oligometastatic non-small cell lung cancerPemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumabTargeting the estrogen pathway for the treatment and prevention of lung cancerA laboratory prognostic index model for patients with advanced non-small cell lung cancerPhase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer.Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma: a phase III randomized trial of the Spanish Lung Cancer Group.Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel.A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma.First- and second-line treatment of advanced metastatic non-small-cell lung cancer: a global view.Thoracic Vertebral Body Irradiation Contributes to Acute Hematologic Toxicity During Chemoradiation Therapy for Non-Small Cell Lung Cancer.Biostatistics: a toolkit for exploration, validation, and interpretation of clinical data.Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer.Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial.Laparoscopic adrenalectomy for cancer.Intratumoral Metabolic Heterogeneity for Prediction of Disease Progression After Concurrent Chemoradiotherapy in Patients with Inoperable Stage III Non-Small-Cell Lung Cancer.Early lung cancer in the elderly: sublobar resection provides equivalent long-term survival in comparison with lobectomy.Gemcitabine for the treatment of advanced nonsmall cell lung cancerPrognostic evaluation of primary non-small cell lung carcinoma patients using biological fluid variables. A systematic review.Statistical learning methods as a preprocessing step for survival analysis: evaluation of concept using lung cancer dataPretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer.Management of non-small cell lung cancer with oligometastasisTreatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies.Research priorities in geriatric oncology for 2013 and beyond.Smoking and prognostic factors in an observational setting in patients with advanced non-small cell lung carcinomaUsing claims-based measures to predict performance status score in patients with lung cancerEligibility for bevacizumab as an independent prognostic factor for patients with advanced non-squamous non-small cell lung cancer: a retrospective cohort study.Standards of care for anemia management in oncology: focus on lung carcinoma.Platinum drugs in the treatment of non-small-cell lung cancerLung cancer--where are we today? Current advances in staging and nonsurgical treatment.Safety and efficacy of vinorelbine in the treatment of non-small cell lung cancerEvaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY.Screening older cancer patients for a Comprehensive Geriatric Assessment: A comparison of three instruments.A novel paradigm in the treatment of oligometastatic non-small cell lung cancer.Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy.Surgical treatment of stage IV non-small cell lung cancer.Prognostic Factors in Advanced Non-Small-Cell Lung Cancer Patients: Patient Characteristics and Type of Chemotherapy.
P2860
Q24200518-49EC979F-EA25-433B-8F7B-DC4C697B44EFQ24243664-78F78DE4-2FA5-4DA2-AA37-B850C1BF20FCQ26749492-6708CF01-D917-4197-A1B9-E298506FC92FQ28067370-E43EA56E-E388-4536-88F0-D0FDB5B43485Q28081243-8436D9A9-B44E-4F7B-AD79-C8199682710CQ28388270-79FD6D58-1F46-491B-B967-9145A9F12C4FQ28397456-3A1D32F4-3F09-4AB9-AB8E-80444F0C0ABFQ28542513-E080060B-D7B3-4775-AD53-A27F41692C8EQ33311607-C79AA7DD-2DAA-4994-95EA-11AE4B9214EEQ33328264-1C1818C0-5ACC-4F9B-8669-9FB04F1C0BC3Q33338040-0C771E6E-EC29-4594-A644-11DD5D35A53CQ33344553-99629AA8-DFFF-4958-BFDA-76C837DD8601Q33373493-4FB18D63-F626-4C9C-B4B0-56CE6F5A6388Q33428648-B708C267-FEFC-43E4-9D1E-B61695DAA518Q33518386-C7521994-A4AE-440E-A19A-6C5CB1CE283FQ33600434-8F7D804A-5460-4998-9985-E70E1DCC9738Q33613709-110AE959-ACD7-472E-8319-45821B911EDBQ33638063-AF973A23-6B2E-4994-82AA-880AE994CA3CQ33669810-996F815D-40B0-4E61-AA3C-9EFD8D167895Q33799220-B1CEB682-84E6-4315-BA15-507DB95F9D68Q33915997-E48F7207-E0F8-4359-90EB-7EA2E4E183ABQ34004381-9B28F4FC-36A5-4573-B8DE-7BBE27C59407Q34070137-CD659FC0-2A48-43A1-86C6-177AC8B49E92Q34196497-B47C9F96-8868-40ED-B67F-2B576F278FAEQ34246641-270F3459-747F-4499-85F4-39D8FE736C6AQ34325219-E389659E-7374-4510-9277-DFEEBD37ED8AQ34386081-6CFD63AD-DEE1-4B31-B2D6-3B3620864A5CQ34487100-B7F7648A-EF52-4708-8764-9017CA4292C8Q34609460-DDC716A6-03BF-4401-A1BC-7C1FB6E13E0FQ34651916-25911FE7-1313-4FE2-B990-381FAB9A9622Q34810857-E2718F55-16CA-4110-985B-B888A3B137C0Q34954760-0B59F006-5077-4CB1-9364-A9E9BB7DBB30Q34982142-76ABBEA8-026B-4702-A132-E62CA613D2C4Q35052543-22E4CB1B-1FC9-4496-9FED-88CCAE0C5F0FQ35104268-910FA2A7-E2D6-413D-9521-D31D6864BB8DQ35214123-FE516740-E0A5-429A-8E40-E23912A2C2A9Q35667792-EAC5398C-7404-4E52-A418-2F9C3F5DD011Q35696941-6024E577-69F6-4481-B384-7FFD17B57F73Q35758398-5323870B-E3AE-48F3-8F19-5BC86EFE0E37Q35763231-64DBD4ED-08AC-4325-AEC5-FF64387A4F2F
P2860
Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience.
description
1991 nî lūn-bûn
@nan
1991 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Survival determinants in exten ...... est Oncology Group experience.
@ast
Survival determinants in exten ...... est Oncology Group experience.
@en
type
label
Survival determinants in exten ...... est Oncology Group experience.
@ast
Survival determinants in exten ...... est Oncology Group experience.
@en
prefLabel
Survival determinants in exten ...... est Oncology Group experience.
@ast
Survival determinants in exten ...... est Oncology Group experience.
@en
P2093
P1476
Survival determinants in exten ...... est Oncology Group experience.
@en
P2093
J J Crowley
K S Albain
R B Livingston
P304
P356
10.1200/JCO.1991.9.9.1618
P407
P577
1991-09-01T00:00:00Z